Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles
摘要:
Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepared and tested for their ability to inhibit p38 MAP kinase and TNF-alpha release. These compounds were prepared by using different synthetic routes. They were tested by applying a nonradioactive p38 MAP kinase assay and by measurement of TNF-a release in human whole blood. Potent inhibitors (IC(50)values in the low nanomolar range, as low as 2 nM in the enzyme assay and 37 nM in the human whole blood test) were identified by variation of substituents at the imidazole-C2-thio position as well as at the 2-aminopyridinyl functionality. In contrast to other known kinase inhibitors, these novel imidazole derivatives with the substituents at the imidazole-C2-thio position may interact with the ribose as well as with the phosphate binding site of the p38 MAP kinase.
A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.
2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
申请人:Burnet Michael
公开号:US20090270462A1
公开(公告)日:2009-10-29
The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof.
这项发明涉及到式I的2-硫代咪唑衍生物,以及其使用方法。
US8143294B2
申请人:——
公开号:US8143294B2
公开(公告)日:2012-03-27
US9617221B2
申请人:——
公开号:US9617221B2
公开(公告)日:2017-04-11
[EN] KINASE MODULATORS FOR THE TREATMENT OF CANCER<br/>[FR] MODULATEURS DE KINASE POUR LE TRAITEMENT DU CANCER
申请人:SYNOVO GMBH
公开号:WO2011100769A2
公开(公告)日:2011-08-18
A method of treating cancer in which a compound that inhibits the expression, production or release of IL-IO by immune cells is combined with a compound that stimulates the production of IL- 12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.